Advanced Ovarian CancerPhase 3DUO-ONCT03737643
Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients
A Phase 3 study testing Bevacizumab, Durvalumab and Olaparib in people with Advanced Ovarian Cancer, run by AstraZeneca at 214 sites in 20 countries.
Trial summary
This is a Phase III randomised, double-blind, multi-centre study to evaluate the efficacy and safety of durvalumab in combination with standard of care platinum based chemotherapy and bevacizumab followed by maintenance durvalumab and bevacizumab or durvalumab, bevacizumab and olaparib in patients with newly diagnosed… Read more about this study
- Who is it for?
- Ages 18 to 130 years, women only
- Conditions the study is for
- Advanced Ovarian Cancer
- What is being tested?
- Bevacizumab, Durvalumab and Olaparib
- Type of treatment
- Pill or oral medicine, Injection or infusion
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 1,407 participants
- Where
- 214 sitesin 20 countries
- Study dates
- 4 Jan 2019to 23 Dec 2026
- Phase
- Phase 3
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 130 years
- Women only
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Female patients with newly diagnosed, histologically confirmed, advanced (Stage III-IV) high grade epithelial ovarian cancer including high grade serious, high grade endometriod, clear cell ovarian cancer or carcinosarcoma, primary peritoneal cancer and / or fallopian-tube cancer
- Patients must be aged ≥18 years of age. For patients enrolled in Japan that are aged <20 year
- All patients should be candidates for cytoreductive surgery either: upfront primary surgery OR plan to undergo chemotherapy with interval debulking surgery
- Evidence of presence or absence of BRCA1/2 mutation in tumour tissue
- Mandatory provision of tumour sample for centralised tBRCA testing
- ECOG performance status 0-1
- Patients must have preserved organ and bone marrow function
- Postmenopausal or evidence of non-childbearing status for women of childbearing potential: negative urine or serum pregnancy test
Who cannot join
- Non-epithelial ovarian cancer, borderline tumors, low grade epithelial tumors or mucinous histology
- Prior systemic anti-cancer therapy for ovarian cancer
- Inability to determine the presence or absence of a deleterious or suspected deleterious BRCA mutation
- Prior treatment with PARP inhibitor or immune mediated therapy
- Planned intraperitoneal cytotoxic chemotherapy
- Active or prior documented autoimmune or inflammatory disorders
Show all 17Show fewer
- Patients considered a poor medical risk due to a serious, uncontrolled intercurrent illness
- Clinically significant cardiovascular disease
- Patients with known brain metastases
- History of another primary malignancy except for:
- Malignancy treated with curative intent and with no known active disease ≥5 years before the first dose of study treatment and of low potential risk for recurrence (patients who have received prior adjuvant chemotherapy for early stage breast cancer may be eligible, provided that it was completed ≥3 years prior to registration, and that the patient remains free of recurrent or metastatic disease)
- Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease
- Adequately treated carcinoma in situ without evidence of disease
- Endometrial cancer FIGO Stage IA, Grade 1 or Grade 2
- Persistent toxicities CTCAE Grade >2 caused by previous cancer therapy
- Patients with a known hypersensitivity to olaparib, durvalumab or any of the excipients of these products and to the combination/comparator agents
- Breast feeding women
Trial locations and contacts
214 sites in 20 countries.
214 sites in 20 countries
Germany41 sites
Research Site
Bad Homburg, 61352
Research Site
Berlin, 10117
Research Site
Bielefeld, 33604
Research Site
Bonn, 53105
Research Site
Brandenburg, 14770
Research Site
Cologne, 50935
Research Site
Dresden, 1307
Research Site
Düsseldorf, 40489
Research Site
Essen, 45136
Research Site
Essen, 45147
Research Site
Esslingen am Neckar, 73730
Research Site
Frankfurt, 60590
Research Site
Freiburg im Breisgau, 79106
Research Site
Fürth, 90766
Research Site
Greifswald, 17475
Research Site
Gütersloh, 33332
Research Site
Hamburg, 20246
Research Site
Hamburg, 20357
Research Site
Hamburg, 22457
Research Site
Hanover, 30177
Research Site
Hanover, 30625
Research Site
Jena, 07747
Research Site
Karlsruhe, 76133
Research Site
Karlsruhe, 76135
Research Site
Kassel, 34125
Research Site
Kiel, 24105
Research Site
Leipzig, 04103
Research Site
Lübeck, 23538
Research Site
Ludwigsburg, 71640
Research Site
Mainz, 55131
Research Site
Mannheim, 68167
Research Site
München, 81377
Research Site
Offenbach, 63069
Research Site
Oldenburg, 26133
Research Site
Rosenheim, 83022
Research Site
Rostock, 18057
Research Site
Saalfeld, 07318
Research Site
Schweinfurt, 97422
Research Site
Tübingen, 72016
Research Site
Ulm, 89075
Research Site
Worms, 67550
China31 sites
Research Site
Beijing, 100026
Research Site
Beijing, CN-100730
Research Site
Bengbu, 233004
Research Site
Changchun, 130021
Research Site
Changsha, 410008
Research Site
Changsha, 430033
Research Site
Chengdu, 610041
Research Site
Chongqing, 400030
Research Site
Dalian, 116001
Research Site
Guangzhou, 510060
Research Site
Guangzhou, 510080
Research Site
Hangzhou, 310009
Research Site
Hangzhou, 310022
Research Site
Harbin, 150081
Research Site
Hefei, 230031
Research Site
Jinhua, 321099
Research Site
Kunming, 650118
Research Site
Lanzhou, 730030
Research Site
Luzhou, 646099
Research Site
Nanchong, 637000
Research Site
Nanjing, 2100008
Research Site
Nanning, 530021
Research Site
Nantong, 226361
Research Site
Shanghai, 200011
Research Site
Shanghai, 200032
Research Site
Wuhan, 430030
Research Site
Wuhan, 430060
Research Site
Xi'an, 710061
Research Site
Zhengzhou, 450002
Research Site
Zhengzhou, 450008
Research Site
Zhuhai, 519099
United States26 sites
Research Site
Albany, New York, 12208
Research Site
Augusta, Georgia, 30912
Research Site
Cleveland, Ohio, 44195
Research Site
Dayton, Ohio, 45429
Research Site
Detroit, Michigan, 48202
Research Site
Durham, North Carolina, 27710
Research Site
Foothill Ranch, California, 92610
Research Site
Hilliard, Ohio, 43026
Research Site
Hinsdale, Illinois, 60521
Research Site
Indianapolis, Indiana, 46202
Research Site
Lancaster, Pennsylvania, 17601
Research Site
Los Angeles, California, 90095
Research Site
Middletown, New Jersey, 07748
Research Site
Montvale, New Jersey, 07645
Research Site
New York, New York, 10065
Research Site
Orange, California, 92868-3298
Research Site
Philadelphia, Pennsylvania, 19104
Research Site
Philadelphia, Pennsylvania, 19107-5097
Research Site
Pittsburgh, Pennsylvania, 15224
Research Site
Salt Lake City, Utah, 84112
Research Site
San Francisco, California, 94158
Research Site
Springfield, Missouri, 65807
Research Site
Tampa, Florida, 33612
Research Site
Towson, Maryland, 21204
Research Site
Tulsa, Oklahoma, 74134
Research Site
Uniondale, New York, 11553
Japan15 sites
Research Site
Fukuoka, 811-1395
Research Site
Kashiwa-shi, 277-8567
Research Site
Kobe, 650-0047
Research Site
Kōtoku, 135-8550
Research Site
Kurume-shi, 830-0011
Research Site
Kyoto, 606-8507
Research Site
Minatoku, 105-8471
Research Site
Nagoya, 464-8681
Research Site
Niigata, 951-8520
Research Site
Okayama, 700-8558
Research Site
Sapporo, 003-0804
Research Site
Sendai, 980-8574
Research Site
Shinjuku-ku, 160-8582
Research Site
Sunto-gun, 411-8777
Research Site
Toyoake-shi, 470-1192
Italy12 sites
Research Site
Brescia, 25123
Research Site
Lecce, 73100
Research Site
Lecco, 23900
Research Site
Milan, 20132
Research Site
Milan, 20141
Research Site
Mirano, 30035
Research Site
Naples, 80131
Research Site
Reggio Calabria, 89100
Research Site
Reggio Emilia, 42100
Research Site
Roma, 00168
Research Site
Torino, 10126
Research Site
Torino, 10128
France11 sites
Research Site
Besançon, 25000
Research Site
Bordeaux, 33076
Research Site
Limoges, 87042
Research Site
Lyon, 69373
Research Site
Marseille, 13273
Research Site
Nantes, 44202
Research Site
Paris, 75012
Research Site
Paris, 75015
Research Site
Paris, 75674
Research Site
Saint-Herblain, 44805
Research Site
Vandœuvre-lès-Nancy, 54519
Brazil9 sites
Research Site
Barretos, 14784-400
Research Site
Florianópolis, 88034-000
Research Site
Fortaleza, 60810-180
Research Site
Londrina, 86015-520
Research Site
Porto Alegre, 90020-090
Research Site
Porto Alegre, 90110-270
Research Site
Rio de Janeiro, 20220-410
Research Site
São Paulo, 01317-000
Research Site
São Paulo, 04014-002
Canada9 sites
Research Site
Barrie, Ontario, L4M 6M2
Research Site
Calgary, Alberta, T2N 5G2
Research Site
Greater Sudbury, Ontario, P3E 5J1
Research Site
Montreal, Quebec, H2X 3E4
Research Site
Montreal, Quebec, H3T 1E2
Research Site
Montreal, Quebec, H4A 3J1
Research Site
Québec, Quebec, G1J 1Z4
Research Site
Rimouski, Quebec, G5L 5T1
Research Site
Toronto, Ontario, M5G 2M9
Hungary7 sites
Research Site
Budapest, 1062
Research Site
Budapest, 1122
Research Site
Debrecen, 4032
Research Site
Győr, 9024
Research Site
Kaposvár, 7400
Research Site
Szeged, 6725
Research Site
Zalaegerszeg, 8900
Peru7 sites
Research Site
Bellavista, CALLAO 2
Research Site
La Libertad, 13013
Research Site
Lima, LIMA 31
Research Site
Lima, Lima 32
Research Site
Lima, LIMA 34
Research Site
Lima, LIMA 41
Research Site
San Isidro, 27
Spain7 sites
Research Site
Córdoba, 14004
Research Site
Madrid, 28033
Research Site
Madrid, 28034
Research Site
Madrid, 28040
Research Site
Madrid, 28041
Research Site
Terrassa(Barcelona), 08221
Research Site
Vigo, 36312
South Korea6 sites
Research Site
Goyang-si, 10408
Research Site
Seongnam-si, 13620
Research Site
Seoul, 03080
Research Site
Seoul, 03722
Research Site
Seoul, 06351
Research Site
Suwon, 16499
Turkey (Türkiye)6 sites
Research Site
Adana, 1260
Research Site
Ankara, 06230
Research Site
Ankara, 06490
Research Site
Istanbul, 34093
Research Site
Istanbul, 34384
Research Site
Izmir, 35100
Belgium5 sites
Research Site
Aalst, 9300
Research Site
Leuven, 3000
Research Site
Namur, 5000
Research Site
Ostend, 8400
Research Site
Sint-Niklaas, 9100
Denmark5 sites
Research Site
Aalborg, 9000
Research Site
Aarhus N, 8200
Research Site
Odense, 5000
Research Site
Roskilde, 4000
Research Site
Vejle, 7100
Poland5 sites
Research Site
Gdynia, 81-519
Research Site
Lodz, 93-513
Research Site
Szczecin, 70-111
Research Site
Warsaw, 02-781
Research Site
Warsaw, 04-141
Austria4 sites
Research Site
Graz, 8036
Research Site
Innsbruck, 6020
Research Site
Linz, 4020
Research Site
Vienna, 1090
Bulgaria4 sites
Research Site
Burgas, 8000
Research Site
Plovdiv, 4004
Research Site
Sofia, 1330
Research Site
Varna, 9000
Finland3 sites
Research Site
Kuopio, 70210
Research Site
Oulu, 90029
Research Site
Turku, 20521
About this study
Official title: A Phase III Randomised, Double-Blind, Placebo-Controlled, Multicentre Study of Durvalumab in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib in Newly Diagnosed Advanced Ovarian Cancer Patients (DUO-O).
This is a Phase III randomised, double-blind, multi-centre study to evaluate the efficacy and safety of durvalumab in combination with standard of care platinum based chemotherapy and bevacizumab followed by maintenance durvalumab and bevacizumab or durvalumab, bevacizumab and olaparib in patients with newly diagnosed advanced ovarian cancer.
Read the detailed description
Eligible patients will be those patients with newly diagnosed, histologically confirmed advanced (Fédération Internationale de Gynécologie et d'Obstétrique [FIGO] Stage III-IV) ovarian, primary peritoneal cancer and/or fallopian-tube cancer. All patients should be candidates for cytoreductive surgery which could be conducted as immediate upfront primary surgery following diagnosis or can be conducted after initiation of platinum based neoadjuvant chemotherapy. All patients should be eligible to start first line platinum based chemotherapy in combination with bevacizumab.
The study aims to evaluate the efficacy and safety of standard of care (SoC) platinum-based chemotherapy and bevacizumab followed by maintenance bevacizumab either as monotherapy, or in combination with durvalumab, or in combination with durvalumab and olaparib. Therefore, this study aims to see which combination allows patients to live longer without the cancer coming back or getting worse. The study is also looking to see which combination makes patients live longer and how the treatment and the cancer affects their quality of life.
- Conditions
- Advanced Ovarian Cancer
- Being tested
- Bevacizumab, Durvalumab, Olaparib, Placebo olaparib, Durvalumab placebo
- Keywords
- Advanced Ovarian Cancer, Ovarian neoplasms
- Medical subject headings
- Ovarian Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
BevacizumabDrug
Bevacizumab by intravenous infusion. In tBRCAm cohort bevacizumab is optional according to local practice.
DurvalumabDrug
Durvalumab by intravenous infusion
OlaparibDrug
Olaparib tablets
Placebo olaparibDrug
Placebo tablets to match olaparib
Durvalumab placeboDrug
Matching placebo for intravenous infusion
Carboplatin+PaclitaxelDrug
Standard of care chemotherapy
| Study group | Role | What they receive |
|---|---|---|
| Arm 1 | Active comparator | Platinum-based chemotherapy in combination with bevacizumab and durvalumab placebo (saline IV infusion) followed by maintenance bevacizumab, durvalumab placebo (saline IV infusion) and olaparib placebo (tablets). Receives: Drug: Bevacizumab; Drug: Placebo olaparib; Drug: Durvalumab placebo; Drug: Carboplatin+Paclitaxel |
| Arm 2 | Experimental | Platinum-based chemotherapy in combination with bevacizumab and durvalumab followed by maintenance bevacizumab, durvalumab and olaparib placebo. Receives: Drug: Bevacizumab; Drug: Durvalumab; Drug: Placebo olaparib; Drug: Carboplatin+Paclitaxel |
| Arm 3 | Experimental | Platinum-based chemotherapy in combination with bevacizumab and durvalumab followed by maintenance bevacizumab, durvalumab and olaparib. Receives: Drug: Bevacizumab; Drug: Durvalumab; Drug: Olaparib; Drug: Carboplatin+Paclitaxel |
| tBRCAm cohort | Experimental | Platinum-based chemotherapy in combination with bevacizumab and durvalumab followed by maintenance bevacizumab, durvalumab and olaparib. Bevacizumab is optional according to local practice. Receives: Drug: Bevacizumab; Drug: Durvalumab; Drug: Olaparib; Drug: Carboplatin+Paclitaxel |
What is being measured
The primary outcome is the main question the study is designed to answer.
Progression-free Survival (PFS) by Investigator Assessment Using Modified RECIST 1.1 - Full Analysis Set
To determine the efficacy of durvalumab in combination with platinum based chemotherapy and bevacizumab and continued as maintenance in combination with bevacizumab and olaparib versus SoC platinum based chemotherapy in combination with bevacizumab by assessment of PFS (using investigator assessment according to Response Evaluation Criteria in Solid Tumours version 1.1 [RECIST 1.1]) in the first line treatment of patients with newly diagnosed advanced ovarian cancer.
Per MTP, the comparison of SoC+D+O v SoC in the Non-tbRCAm patients is a primary endpoint. SoC+D v SoC is reported separately as a secondary endpoint. Results for tBRCAm SoC+D+O are not presented as this was prespecified to be assessed only in the Non-tBRCAm patients.
Measured: At baseline, within 3 weeks of last dose of chemotherapy, then every 12 weeks for 3 years and thereafter every 24 weeks. Assessed until primary analysis - (05DEC2022 for Global cohort, 17MAR2025 for China cohort) - upto 46 months
Progression-free Survival (PFS) by Investigator Assessment Using Modified RECIST 1.1 - (Full Analysis Set, HRD Positive)
To determine the efficacy of durvalumab and olaparib assessed by PFS in the first line treatment of patients with newly diagnosed advanced ovarian cancer.
Per MTP, the comparison of SoC+D+O v SoC in the Non-tBRCAm HRD positve population is a primary endpoint. SoC+D v SoC is reported separately as a secondary endpoint. Results for tBRCAm SoC+D+O are not presented as as this was prespecified to be assessed only in the Non-tBRCAm patients.
Measured: At baseline, within 3 weeks of last dose of chemotherapy, then every 12 weeks for 3 years and thereafter every 24 weeks. Assessed until DCO1 - (05DEC2022 for Global cohort, 17MAR2025 for China cohort) - upto 46 months
Secondary outcomes (22)
Progression-free Survival (PFS) by Investigator Assessment Using Modified RECIST 1.1 - Full Analysis Set
To determine the efficacy of durvalumab assessed by PFS in the first line treatment of patients with newly diagnosed advanced ovarian cancer.
Per MTP, the comparison of SoC+D v SoC is a secondary endpoint. SoC+D+O v SoC is reported separately as a primary endpoint. Results for tBRCAm SoC+D+O are not presented as this was prespecified to be assessed only in the Non-tBRCAm patients.
Measured: At baseline, within 3 weeks of last dose of chemotherapy, then every 12 weeks for 3 years and thereafter every 24 weeks. For global cohort, assessed until DCO2 (18SEP2023) - up to 55 months. For China cohort assessed until DCO1 (17MAR2025) - 46 months.
Overall Survival - Full Analysis Set
To determine the efficacy of durvalumab and olaparib assessed by OS in the first line treatment patients with newly diagnosed advanced ovarian cancer.
Overall survival (OS) is defined as the time from randomisation/allocation to death due to any cause regardless of whether the patient withdraws from randomised therapy or receives another anti-cancer therapy.
Results for tBRCAm SoC+D+O are not presented as this was prespecified to be assessed only in the Non-tBRCAm patients.
Measured: Survival assessed every 12 weeks after RECIST 1.1 defined progression. For global cohort, assessed until DCO3 (17MAR2025) - up to 73 months. For China cohort assessed until DCO1 (17MAR2025) - up to 46 months.
Overall Survival - (Full Analysis Set, HRD-positive)
To determine the efficacy of durvalumab and olaparib assessed by OS in the first line treatment patients with newly diagnosed advanced ovarian cancer.
Overall survival (OS) is defined as the time from randomisation/allocation to death due to any cause regardless of whether the patient withdraws from randomised therapy or receives another anti-cancer therapy.
Results for tBRCAm SoC+D+O are not presented as this was prespecified to be assessed only in the Non-tBRCAm patients.
Measured: Survival assessed every 12 weeks after RECIST 1.1 defined progression. For global cohort, assessed until DCO3 (17MAR2025) - up to 73 months. For China cohort assessed until DCO1 (17MAR2025) - up to 46 months.
Time to Second Progression or Death Based on Local Standard Clinical Practice (PFS2) - Full Analysis Set
To assess the efficacy of durvalumab and olaparib in terms of PFS2 in the first line treatment of patients with newly diagnosed advanced ovarian cancer.
Time to second progression or death (PFS2) is defined as the time from the date of randomisation/allocation to the earliest of the progression event subsequent to first subsequent therapy or death.
Results for tBRCAm SoC+D+O are not presented as this was prespecified to be assessed only in the Non-tBRCAm patients.
Measured: Assessed every 12 weeks after RECIST 1.1 defined progression. For global cohort, assessed until DCO3 (17MAR2025) - up to 73 months. For China cohort assessed until DCO1 (17MAR2025) - 46 months.
Time to Second Progression or Death Based on Local Standard Clinical Practice (PFS2) - (Full Analysis Set, HRD-positive)
To assess the efficacy of durvalumab and olaparib in terms of PFS2 in the first line treatment of patients with newly diagnosed advanced ovarian cancer.
Time to second progression or death (PFS2) is defined as the time from the date of randomisation/allocation to the earliest of the progression event subsequent to first subsequent therapy or death.
Results for tBRCAm SoC+D+O are not presented as this was prespecified to be assessed only in the Non-tBRCAm patients.
Measured: Assessed every 12 weeks after RECIST 1.1 defined progression. For global cohort, assessed until DCO3 (17MAR2025) - up to 73 months. For China cohort assessed until DCO1 (17MAR2025) - 46 months.
Objective Response Rate Based on Investigator Assessment (Full Analysis Set)
To assess the efficacy of durvalumab and olaparib in terms of ORR (Complete Response + Partial Response) by investigator assessment by modified RECIST 1.1:
- in all patients with evaluable disease at baseline
- prior to surgery in those patients planned to have IDS with evaluable disease at baseline.
Objective response rate (ORR) is defined similarly for the non-tBRCAm and tBRCAm cohorts as the number (percentage) of patients with at least one investigator-assessed visit response of CR or PR and will be based on a subset of all randomised/allocated patients who have evaluable disease at baseline per the site investigator.
Measured: At baseline, within 3 weeks of last dose of chemotherapy, then every 12 weeks for 3 years and thereafter every 24 weeks. Up to 55 months for global non-tBRCAm (DCO2 18SEP2023). Up to 46 for Global tBRCAm (DCO1 05DEC2022) and China (DCO1 17MAR2025)
Objective Response Rate Based on Investigator Assessment (Full Analysis Set, HRD-positive)
To assess the efficacy of durvalumab and olaparib in terms of ORR (Complete Response + Partial Response) by investigator assessment by modified RECIST 1.1
- in all patients with evaluable disease at baseline
- prior to surgery in those patients planned to have IDS with evaluable disease at baseline.
Objective response rate (ORR) is defined similarly for the non-tBRCAm and tBRCAm cohorts as the number (percentage) of patients with at least one investigator-assessed visit response of CR or PR and will be based on a subset of all randomised/allocated patients who have evaluable disease at baseline per the site investigator.
This was prespecified to be assessed only in the non-tBRCAm cohort.
Measured: At baseline, within 3 weeks of last dose of chemotherapy, then every 12 weeks for 3 years and thereafter every 24 weeks. Up to 55 months for global non-tBRCAm (DCO2 18SEP2023). Up to 46 for China (DCO1 17MAR2025)
Duration of Objective Response Based on Investigator Assessments (Full Analysis Set)
To assess the efficacy of durvalumab and olaparib in terms of duration of response (DoR) in the first line treatment of patients with newly diagnosed advanced ovarian cancer.
Duration of response (DoR) is defined similarly for the non-tBRCAm and tBRCAm cohorts using the corresponding FAS among patients with a response (CR or PR), as the time from the date of first documented response (i.e., the first time at which the visit response is PR or CR) according to modified RECIST v1.1 as assessed by the investigator until date of documented progression or death in the absence of disease progression.
This was prespecified to be assessed only in the Global patients.
Measured: At baseline, within 3 weeks of last dose of chemotherapy, then every 12 weeks for 3 years and thereafter every 24 weeks. Up to 55 months for global non-tBRCAm (DCO2 18SEP2023). Up to 46 for Global tBRCAm (DCO1 05DEC2022)
Duration of Objective Response Based on Investigator Assessments (Full Analysis Set, HRD-positive)
To assess the efficacy of durvalumab and olaparib in terms of duration of response (DoR) in the first line treatment of patients with newly diagnosed advanced ovarian cancer.
Duration of response (DoR) is defined similarly for the non-tBRCAm and tBRCAm cohorts using the corresponding FAS among patients with a response (CR or PR), as the time from the date of first documented response (i.e., the first time at which the visit response is PR or CR) according to modified RECIST v1.1 as assessed by the investigator until date of documented progression or death in the absence of disease progression.
This was prespecified to be assessed only in Global Non-tBRCAm patients.
Measured: At baseline, within 3 weeks of last dose of chemotherapy, then every 12 weeks for 3 years and thereafter every 24 weeks. Up to 55 months for global non-tBRCAm (DCO2 18SEP2023).
Time to First Subsequent Therapy (TFST) - Full Analysis Set
To assess the efficacy of durvalumab and olaparib in terms of TFST in the first line treatment of patients with newly diagnosed advanced ovarian cancer.
Time to start of first subsequent therapy or death (TFST) is defined as the time from randomisation/allocation to the earlier of first subsequent therapy start date following study treatment discontinuation, or death.
This was prespecified to be assessed only in Non-tBRCAm patients.
Measured: Assessed every 12 weeks following treatment discontinuation. For global cohort, assessed until DCO3 (17MAR2025) - up to 73 months. For China cohort assessed until DCO1 (17MAR2025) - up to 46 months.
Time to First Subsequent Therapy (TFST) - (Full Analysis Set, HRD-positive)
To assess the efficacy of durvalumab and olaparib in terms of TFST in the first line treatment of patients with newly diagnosed advanced ovarian cancer.
Time to start of first subsequent therapy or death (TFST) is defined as the time from randomisation/allocation to the earlier of first subsequent therapy start date following study treatment discontinuation, or death.
This was prespecified to be assessed only in Non-tBRCAm patients.
Measured: Assessed every 12 weeks following treatment discontinuation. For global cohort, assessed until DCO3 (17MAR2025) - up to 73 months. For China cohort assessed until DCO1 (17MAR2025) - up to 46 months.
Time to Second Subsequent Therapy (TSST) - Full Analysis Set
To assess the efficacy of durvalumab and olaparib in terms of TSST in the first line treatment of patients with newly diagnosed advanced ovarian cancer.
Time to second subsequent therapy or death (TSST) is defined as the time from randomisation/allocation to the earlier of the second subsequent anti-cancer therapy start date following study treatment discontinuation, or death.
This was prespecified to be assessed only in Non-tBRCAm patients.
Measured: Assessed every 12 weeks following treatment discontinuation. For global cohort, assessed until DCO3 (17MAR2025) - up to 73 months. For China cohort assessed until DCO1 (17MAR2025) - up to 46 months.
Time to Second Subsequent Therapy (TSST) - (Full Analysis Set, HRD-positive)
To assess the efficacy of durvalumab and olaparib in terms of TSST in the first line treatment of patients with newly diagnosed advanced ovarian cancer.
Time to second subsequent therapy or death (TSST) is defined as the time from randomisation to the earlier of the second subsequent anti-cancer therapy start date following study treatment discontinuation, or death.
This was prespecified to be assessed only in Non-tBRCAm patients.
Measured: Assessed every 12 weeks following treatment discontinuation. For global cohort, assessed until DCO3 (17MAR2025) - up to 73 months. For China cohort assessed until DCO1 (17MAR2025) - up to 46 months.
Time to Treatment Discontinuation (TDT) - Full Analysis Set
To assess the efficacy of durvalumab and olaparib in terms of TDT in the first line treatment of patients with newly diagnosed advanced ovarian cancer.
Time to permanent study treatment discontinuation or death (TDT) is defined as the time from randomisation/allocation to the earlier of the date of permanent study treatment discontinuation or death.
This was prespecified to be assessed only in Non-tBRCAm patients.
Measured: Assessed through study completion, up to 73 months for global non-tBRCAm (DCO3 17MAR2025) and up to 46 months for and China (DCO1 17MAR2025)
Time to Treatment Discontinuation (TDT) - (Full Analysis Set, HRD-positive)
To assess the efficacy of durvalumab and olaparib in terms of TDT in the first line treatment of patients with newly diagnosed advanced ovarian cancer.
Time to permanent study treatment discontinuation or death (TDT) is defined as the time from randomisation/allocation to the earlier of the date of permanent study treatment discontinuation or death.
This was prespecified to be assessed only in Non-tBRCAm patients.
Measured: Assessed through study completion, up to 73 months for global non-tBRCAm (DCO3 17MAR2025) and up to 46 months for and China (DCO1 17MAR2025)
Change From Baseline in Physical Function Score of the EORTC-QLQ-C30 and EORTC-QLQ-OV28 Questionnaires - Full Analysis Set
To determine the effects on HRQoL, global health status and ovarian cancer symptoms of the combination of durvalumab and olaparib in the first line treatment of non-tBRCAm patients with newly diagnosed advanced ovarian cancer. The physical functioning score is a score from 0 to 100. Higher scores on the physical functioning score indicate better health status/function.
This was prespecified to be assessed only in Global Non-tBRCAm patients.
Measured: Assessed at week 96.
Change From Baseline in Physical Function Score of the EORTC-QLQ-C30 and EORTC-QLQ-OV28 Questionnaires - (Full Analysis Set, HRD Positive)
To determine the effects on HRQoL, global health status and ovarian cancer symptoms of the combination of durvalumab and olaparib in the first line treatment of non-tBRCAm patients with newly diagnosed advanced ovarian cancer. The physical functioning score is a score from 0 to 100. Higher scores on the physical functioning score indicate better health status/function.
This was prespecified to be assessed only in Global Non-tBRCAm patients.
Measured: Assessed at week 96.
Change From Baseline in Global Health Status/QoL Score of the EORTC-QLQ-C30 and EORTC-QLQ-OV28 Questionnaires - Full Analysis Set
To determine the effects on HRQoL, global health status and ovarian cancer symptoms of the combination of durvalumab and olaparib in the first line treatment of non-tBRCAm patients with newly diagnosed advanced ovarian cancer. The global health status/quality of life (QoL) is a score from 0 to 100. Higher scores on the global health status/QoL indicate better health status/function.
This was prespecified to be assessed only in Global Non-tBRCAm patients.
Measured: Assessed at week 96.
Change From Baseline in Global Health Status/QoL Score of the EORTC-QLQ-C30 and EORTC-QLQ-OV28 Questionnaires - (Full Analysis Set, HRD Positive)
To determine the effects on HRQoL, global health status and ovarian cancer symptoms of the combination of durvalumab and olaparib in the first line treatment of non-tBRCAm patients with newly diagnosed advanced ovarian cancer. The global health status/quality of life (QoL) is a score from 0 to 100. Higher scores on the global health status/QoL indicate better health status/function.
This was prespecified to be assessed only in Global Non-tBRCAm patients.
Measured: Assessed at week 96
Summary of Serum Concentrations (μg/mL) of Durvalumab for Each Treatment - Non-tBRCAm Cohort With Primary Cytoreductive Surgery (Pharmacokinetic Analysis Set)
To characterize the PK of durvalumab in combination with bevacizumab and olaparib.
This was prespecified to be assessed only in Global Non-tBRCAm patients.
Measured: Assessed at Day 85 pre-dose, Day 183 pre-dose and 3 months after last dose of durvalumab.
Summary of Plasma Concentrations (μg/mL) of Olaparib - Non-tBRCAm Cohort With Primary Cytoreductive Surgery (Pharmacokinetic Analysis Set)
To determine olaparib plasma concentrations via sparse sampling for population PK analyses.
This was prespecified to be assessed only in Global Non-tBRCAm patients.
Measured: Assessed on Day 148 post-dose (1-3 hours, 3-6 hours and 6-12 hours)
Summary of ADA Responses During the Study for Durvalumab - Non-tBRCAm Cohort With Primary Cytoreductive Surgery (ADA Analysis Set)
To characterize the immunogenicity of durvalumab in combination with bevacizumab and olaparib.
This was prespecified to be assessed only in Global Non-tBRCAm patients.
Measured: Assessed pre-infusion at Cycle 2, Cycle 4, Cycle 6 and the third cycle of the maintenance phase as well as 3 months after last dose of durvalumab
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Nov 2018
- Study start4 Jan 2019
- Primary completion17 Mar 2025
- Study completion23 Dec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Advanced Ovarian CancerStudies of the same condition, open and under way.
- More trials run by AstraZenecaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- The study consists of 2 independent cohorts: 3 double-blind treatment arms cohort for patients with no tBRCA mutation, and a single open label arm cohort for patients with tBRCA mutation
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 1,407 participants (actual)
Sponsor and investigators
- Lead sponsor
- AstraZeneca
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- European Network of Gynaecological Oncological Trial Groups (ENGOT), GOG Foundation, Myriad Genetic Laboratories, Inc.
- Responsible party
- Sponsor
- Investigators
- Philipp Harter, Principal investigator, European Network of Gynaecological Oncological Trial Groups (ENGOT)Carol Aghajanian, Principal investigator, GOG
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03737643
- Sponsor's protocol ID
- D081RC00001
- Other IDs
- 2017-004632-11, 2017
- Acronym
- DUO-O
- Status last verified
- Jul 2026
- First submitted
- 15 Oct 2018
- Last updated
- 7 Jul 2026
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- Yes: Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Publications
Gaitskell K, Rogozinska E, Platt S, Chen Y, Abd El Aziz M, Tattersall A, Morrison J. Angiogenesis inhibitors for the treatment of epithelial ovarian cancer. Cochrane Database Syst Rev. 2023 Apr 18;4(4):CD007930. doi: 10.1002/14651858.CD007930.pub3.
PubMed 37185961
Study at a glance
From the registry record, last updated by the sponsor on 7 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase III Randomised, Double-Blind, Placebo-Controlled, Multicentre Study of Durvalumab in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib in Newly Diagnosed Advanced Ovarian Cancer Patients (DUO-O).
- ClinicalTrials.gov ID
- NCT03737643
- Acronym / sponsor ID
- DUO-O / D081RC00001
- Conditions
- Advanced Ovarian Cancer
- Keywords
- Advanced Ovarian Cancer, Ovarian neoplasms
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 1,407 participants (actual)
- Lead sponsor
- AstraZenecaIndustry (pharma, biotech, devices)
- Collaborators
- European Network of Gynaecological Oncological Trial Groups (ENGOT), GOG Foundation, Myriad Genetic Laboratories, Inc.
- Study start
- 4 Jan 2019 (actual)
- Primary completion
- 17 Mar 2025 (actual)
- Study completion
- 23 Dec 2026 (estimated)
- First posted
- 9 Nov 2018 (actual)
- Results
- Posted 9 Jun 2026
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a Phase III randomised, double-blind, multi-centre study to evaluate the efficacy and safety of durvalumab in combination with standard of care platinum based chemotherapy and bevacizumab followed by maintenance durvalumab and bevacizumab or durvalumab, bevacizumab and olaparib in patients with newly diagnosed advanced ovarian cancer.
Detailed description
Eligible patients will be those patients with newly diagnosed, histologically confirmed advanced (Fédération Internationale de Gynécologie et d'Obstétrique [FIGO] Stage III-IV) ovarian, primary peritoneal cancer and/or fallopian-tube cancer. All patients should be candidates for cytoreductive surgery which could be conducted as immediate upfront primary surgery following diagnosis or can be conducted after initiation of platinum based neoadjuvant chemotherapy. All patients should be eligible to start first line platinum based chemotherapy in combination with bevacizumab.
The study aims to evaluate the efficacy and safety of standard of care (SoC) platinum-based chemotherapy and bevacizumab followed by maintenance bevacizumab either as monotherapy, or in combination with durvalumab, or in combination with durvalumab and olaparib. Therefore, this study aims to see which combination allows patients to live longer without the cancer coming back or getting worse. The study is also looking to see which combination makes patients live longer and how the treatment and the cancer affects their quality of life.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 4
- Model description
- The study consists of 2 independent cohorts: 3 double-blind treatment arms cohort for patients with no tBRCA mutation, and a single open label arm cohort for patients with tBRCA mutation
| Arm | Type | Receives |
|---|---|---|
| Arm 1 | Active comparator | Drug: Bevacizumab, Drug: Placebo olaparib, Drug: Durvalumab placebo, Drug: Carboplatin+PaclitaxelPlatinum-based chemotherapy in combination with bevacizumab and durvalumab placebo (saline IV infusion) followed by maintenance bevacizumab, durvalumab placebo (saline IV infusion) and olaparib placebo (tablets). |
| Arm 2 | Experimental | Drug: Bevacizumab, Drug: Durvalumab, Drug: Placebo olaparib, Drug: Carboplatin+PaclitaxelPlatinum-based chemotherapy in combination with bevacizumab and durvalumab followed by maintenance bevacizumab, durvalumab and olaparib placebo. |
| Arm 3 | Experimental | Drug: Bevacizumab, Drug: Durvalumab, Drug: Olaparib, Drug: Carboplatin+PaclitaxelPlatinum-based chemotherapy in combination with bevacizumab and durvalumab followed by maintenance bevacizumab, durvalumab and olaparib. |
| tBRCAm cohort | Experimental | Drug: Bevacizumab, Drug: Durvalumab, Drug: Olaparib, Drug: Carboplatin+PaclitaxelPlatinum-based chemotherapy in combination with bevacizumab and durvalumab followed by maintenance bevacizumab, durvalumab and olaparib. Bevacizumab is optional according to local practice. |
Who may qualify
- Ages
- 18 to 130 years
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (8 listed)
- Female patients with newly diagnosed, histologically confirmed, advanced (Stage III-IV) high grade epithelial ovarian cancer including high grade serious, high grade endometriod, clear cell ovarian cancer or carcinosarcoma, primary peritoneal cancer and / or fallopian-tube cancer
- Patients must be aged ≥18 years of age. For patients enrolled in Japan that are aged <20 year
- All patients should be candidates for cytoreductive surgery either: upfront primary surgery OR plan to undergo chemotherapy with interval debulking surgery
- Evidence of presence or absence of BRCA1/2 mutation in tumour tissue
- Mandatory provision of tumour sample for centralised tBRCA testing
Key exclusion criteria (17 listed)
- Non-epithelial ovarian cancer, borderline tumors, low grade epithelial tumors or mucinous histology
- Prior systemic anti-cancer therapy for ovarian cancer
- Inability to determine the presence or absence of a deleterious or suspected deleterious BRCA mutation
- Prior treatment with PARP inhibitor or immune mediated therapy
- Planned intraperitoneal cytotoxic chemotherapy
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| BevacizumabBevacizumab by intravenous infusion. In tBRCAm cohort bevacizumab is optional according to local practice. | Drug | Arm 1, Arm 2, Arm 3, tBRCAm cohort |
| DurvalumabDurvalumab by intravenous infusion | Drug | Arm 2, Arm 3, tBRCAm cohort |
| OlaparibOlaparib tablets | Drug | Arm 3, tBRCAm cohort |
| Placebo olaparibPlacebo tablets to match olaparib | Drug | Arm 1, Arm 2 |
| Durvalumab placeboMatching placebo for intravenous infusion | Drug | Arm 1 |
| Carboplatin+PaclitaxelStandard of care chemotherapy | Drug | Arm 1, Arm 2, Arm 3, tBRCAm cohort |
Primary outcome
Progression-free Survival (PFS) by Investigator Assessment Using Modified RECIST 1.1 - Full Analysis Set
Time frame: At baseline, within 3 weeks of last dose of chemotherapy, then every 12 weeks for 3 years and thereafter every 24 weeks. Assessed until primary analysis - (05DEC2022 for Global cohort, 17MAR2025 for China cohort) - upto 46 months
To determine the efficacy of durvalumab in combination with platinum based chemotherapy and bevacizumab and continued as maintenance in combination with bevacizumab and olaparib versus SoC platinum based chemotherapy in combination with bevacizumab by assessment of PFS (using investigator assessment according to Response Evaluation Criteria in Solid Tumours version 1.1 [RECIST 1.1]) in the first line treatment of patients with newly diagnosed advanced ovarian cancer. Per MTP, the comparison of SoC+D+O v SoC in the Non-tbRCAm patients is a primary endpoint. SoC+D v SoC is reported separately as a secondary endpoint. Results for tBRCAm SoC+D+O are not presented as this was prespecified to be assessed only in the Non-tBRCAm patients.
Progression-free Survival (PFS) by Investigator Assessment Using Modified RECIST 1.1 - (Full Analysis Set, HRD Positive)
Time frame: At baseline, within 3 weeks of last dose of chemotherapy, then every 12 weeks for 3 years and thereafter every 24 weeks. Assessed until DCO1 - (05DEC2022 for Global cohort, 17MAR2025 for China cohort) - upto 46 months
To determine the efficacy of durvalumab and olaparib assessed by PFS in the first line treatment of patients with newly diagnosed advanced ovarian cancer. Per MTP, the comparison of SoC+D+O v SoC in the Non-tBRCAm HRD positve population is a primary endpoint. SoC+D v SoC is reported separately as a secondary endpoint. Results for tBRCAm SoC+D+O are not presented as as this was prespecified to be assessed only in the Non-tBRCAm patients.
22 secondary outcomes
Progression-free Survival (PFS) by Investigator Assessment Using Modified RECIST 1.1 - Full Analysis Set
Time frame: At baseline, within 3 weeks of last dose of chemotherapy, then every 12 weeks for 3 years and thereafter every 24 weeks. For global cohort, assessed until DCO2 (18SEP2023) - up to 55 months. For China cohort assessed until DCO1 (17MAR2025) - 46 months.
Overall Survival - Full Analysis Set
Time frame: Survival assessed every 12 weeks after RECIST 1.1 defined progression. For global cohort, assessed until DCO3 (17MAR2025) - up to 73 months. For China cohort assessed until DCO1 (17MAR2025) - up to 46 months.
Overall Survival - (Full Analysis Set, HRD-positive)
Time frame: Survival assessed every 12 weeks after RECIST 1.1 defined progression. For global cohort, assessed until DCO3 (17MAR2025) - up to 73 months. For China cohort assessed until DCO1 (17MAR2025) - up to 46 months.
Time to Second Progression or Death Based on Local Standard Clinical Practice (PFS2) - Full Analysis Set
Time frame: Assessed every 12 weeks after RECIST 1.1 defined progression. For global cohort, assessed until DCO3 (17MAR2025) - up to 73 months. For China cohort assessed until DCO1 (17MAR2025) - 46 months.
Time to Second Progression or Death Based on Local Standard Clinical Practice (PFS2) - (Full Analysis Set, HRD-positive)
Time frame: Assessed every 12 weeks after RECIST 1.1 defined progression. For global cohort, assessed until DCO3 (17MAR2025) - up to 73 months. For China cohort assessed until DCO1 (17MAR2025) - 46 months.
Objective Response Rate Based on Investigator Assessment (Full Analysis Set)
Time frame: At baseline, within 3 weeks of last dose of chemotherapy, then every 12 weeks for 3 years and thereafter every 24 weeks. Up to 55 months for global non-tBRCAm (DCO2 18SEP2023). Up to 46 for Global tBRCAm (DCO1 05DEC2022) and China (DCO1 17MAR2025)
Objective Response Rate Based on Investigator Assessment (Full Analysis Set, HRD-positive)
Time frame: At baseline, within 3 weeks of last dose of chemotherapy, then every 12 weeks for 3 years and thereafter every 24 weeks. Up to 55 months for global non-tBRCAm (DCO2 18SEP2023). Up to 46 for China (DCO1 17MAR2025)
Duration of Objective Response Based on Investigator Assessments (Full Analysis Set)
Time frame: At baseline, within 3 weeks of last dose of chemotherapy, then every 12 weeks for 3 years and thereafter every 24 weeks. Up to 55 months for global non-tBRCAm (DCO2 18SEP2023). Up to 46 for Global tBRCAm (DCO1 05DEC2022)
Duration of Objective Response Based on Investigator Assessments (Full Analysis Set, HRD-positive)
Time frame: At baseline, within 3 weeks of last dose of chemotherapy, then every 12 weeks for 3 years and thereafter every 24 weeks. Up to 55 months for global non-tBRCAm (DCO2 18SEP2023).
Time to First Subsequent Therapy (TFST) - Full Analysis Set
Time frame: Assessed every 12 weeks following treatment discontinuation. For global cohort, assessed until DCO3 (17MAR2025) - up to 73 months. For China cohort assessed until DCO1 (17MAR2025) - up to 46 months.
Time to First Subsequent Therapy (TFST) - (Full Analysis Set, HRD-positive)
Time frame: Assessed every 12 weeks following treatment discontinuation. For global cohort, assessed until DCO3 (17MAR2025) - up to 73 months. For China cohort assessed until DCO1 (17MAR2025) - up to 46 months.
Time to Second Subsequent Therapy (TSST) - Full Analysis Set
Time frame: Assessed every 12 weeks following treatment discontinuation. For global cohort, assessed until DCO3 (17MAR2025) - up to 73 months. For China cohort assessed until DCO1 (17MAR2025) - up to 46 months.
Time to Second Subsequent Therapy (TSST) - (Full Analysis Set, HRD-positive)
Time frame: Assessed every 12 weeks following treatment discontinuation. For global cohort, assessed until DCO3 (17MAR2025) - up to 73 months. For China cohort assessed until DCO1 (17MAR2025) - up to 46 months.
Time to Treatment Discontinuation (TDT) - Full Analysis Set
Time frame: Assessed through study completion, up to 73 months for global non-tBRCAm (DCO3 17MAR2025) and up to 46 months for and China (DCO1 17MAR2025)
Time to Treatment Discontinuation (TDT) - (Full Analysis Set, HRD-positive)
Time frame: Assessed through study completion, up to 73 months for global non-tBRCAm (DCO3 17MAR2025) and up to 46 months for and China (DCO1 17MAR2025)
Change From Baseline in Physical Function Score of the EORTC-QLQ-C30 and EORTC-QLQ-OV28 Questionnaires - Full Analysis Set
Time frame: Assessed at week 96.
Change From Baseline in Physical Function Score of the EORTC-QLQ-C30 and EORTC-QLQ-OV28 Questionnaires - (Full Analysis Set, HRD Positive)
Time frame: Assessed at week 96.
Change From Baseline in Global Health Status/QoL Score of the EORTC-QLQ-C30 and EORTC-QLQ-OV28 Questionnaires - Full Analysis Set
Time frame: Assessed at week 96.
Change From Baseline in Global Health Status/QoL Score of the EORTC-QLQ-C30 and EORTC-QLQ-OV28 Questionnaires - (Full Analysis Set, HRD Positive)
Time frame: Assessed at week 96
Summary of Serum Concentrations (μg/mL) of Durvalumab for Each Treatment - Non-tBRCAm Cohort With Primary Cytoreductive Surgery (Pharmacokinetic Analysis Set)
Time frame: Assessed at Day 85 pre-dose, Day 183 pre-dose and 3 months after last dose of durvalumab.
Summary of Plasma Concentrations (μg/mL) of Olaparib - Non-tBRCAm Cohort With Primary Cytoreductive Surgery (Pharmacokinetic Analysis Set)
Time frame: Assessed on Day 148 post-dose (1-3 hours, 3-6 hours and 6-12 hours)
Summary of ADA Responses During the Study for Durvalumab - Non-tBRCAm Cohort With Primary Cytoreductive Surgery (ADA Analysis Set)
Time frame: Assessed pre-infusion at Cycle 2, Cycle 4, Cycle 6 and the third cycle of the maintenance phase as well as 3 months after last dose of durvalumab
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 7 Jul 2026.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Derived from this study: PubMed 37185961Gaitskell K, Rogozinska E, Platt S, Chen Y, Abd El Aziz M, Tattersall A, Morrison J. Angiogenesis inhibitors for the treatment of epithelial ovarian cancer. Cochrane Database Syst Rev. 2023 Apr 18;4(4):CD007930. doi: 10.1002/14651858.CD007930.pub3.
- Redacted CSPLink provided by the sponsor.
- Redacted SAPLink provided by the sponsor.
- Redacted CSR synopsisLink provided by the sponsor.
- CSR synopsis - Global CohortLink provided by the sponsor.
- Individual participant dataSharing planned: Yes. Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Related trials for Advanced Ovarian Cancer
Active, not recruitingPhase 1/2
Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can...
Colorectal Neoplasms, Breast Neoplasms
RecruitingPhase 3
Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Non-Homologous Recombination Deficiency (Non-HRD) Positive Advanced Epithelial Ovarian Cancer
Epithelial Ovarian Cancer
RecruitingPhase 2
At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
Advanced Anal Carcinoma, Advanced Biliary Tract Carcinoma
Active, not recruitingPhase 1
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors
Advanced Solid Tumor
RecruitingPhase 1
A Phase I Study of CG-7321 Monotherapy or Combination Therapy in Advanced Solid Tumors
Advanced Solid Tumors, Breast Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Philipp Harter principal investigator
European Network of Gynaecological Oncological Trial Groups (ENGOT)
Carol Aghajanian principal investigator
GOG
214 sites in 20 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Bevacizumab, Durvalumab and Olaparib in people with Advanced Ovarian Cancer, run by AstraZeneca at 214 sites in 20 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 17 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 7 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 214 sites in Germany, China, United States, Japan, Italy and 15 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 9 Jun 2026). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Progression-free Survival (PFS) by Investigator Assessment Using Modified RECIST 1.1 - Full Analysis Set (time frame: At baseline, within 3 weeks of last dose of chemotherapy, then every 12 weeks for 3 years and thereafter every 24 weeks. Assessed until primary analysis - (05DEC2022 for Global cohort, 17MAR2025 for China cohort) - upto 46 months). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03737643, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Jul 2026.